On the stock market since 2004, it operates in the world of health and science. It has 592 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 47% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 52% a year on average.
The average analyst price target is $9.00 — 111% above today’s price.
The company’s market value is 206 times its annual profit. Even a small disappointment could hit the price hard.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 33/100.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, MNKD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MNKD is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (53/100) says the stock isn’t cheap.